[Seroimmunological changes during therapy with triethylenethiophosphoramide in patients with malignant neoplasms].
D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D001389:Azirines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D007075:Immunoglobulin M / Q000032:analysis*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010756:Phosphoric Acids / Q000627:therapeutic use*; D005719:gamma-Globulins / Q000032:analysis*
D001389:Azirines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010756:Phosphoric Acids; D005719:gamma-Globulins
Modifiche sieroimmunologiche in corso di terapia con trietilentiofosforamide in portatrici di neoplasie maligne.